These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 14727241)

  • 1. Amifostine and external beam radiation therapy and/or high-dose rate brachytherapy in the treatment of localized prostate carcinoma: preliminary results of a phase II trial.
    Linares LA; Echols D
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):58-62. PubMed ID: 14727241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy.
    Dziuk T; Senzer N
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):49-57. PubMed ID: 14727240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
    Ménard C; Camphausen K; Muanza T; Sears-Crouse N; Smith S; Ben-Josef E; Coleman CN
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):63-7. PubMed ID: 14727242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116.
    Small W; Winter K; Levenback C; Iyer R; Hymes SR; Jhingran A; Gaffney D; Erickson B; Greven K
    Int J Gynecol Cancer; 2011 Oct; 21(7):1266-75. PubMed ID: 21892091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
    Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical trial.
    Wynn RB; Mehta V
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S99-104. PubMed ID: 16015543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
    Hu K; Ship JA; Harrison LB
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):40-8. PubMed ID: 14727239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytoprotection/radioprotection with amifostine: potential role in cervical cancer and early findings in the Radiation Therapy Oncology Group C-0116 trial.
    Small W;
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):68-71. PubMed ID: 14727243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
    Antonadou D
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of acute and subacute genitourinary and gastrointestinal adverse events of radiotherapy for prostate cancer using intensity-modulated radiation therapy, three-dimensional conformal radiation therapy, permanent implant brachytherapy and high-dose-rate brachytherapy.
    Morimoto M; Yoshioka Y; Konishi K; Isohashi F; Takahashi Y; Ogata T; Koizumi M; Teshima T; Bijl HP; van der Schaaf A; Langendijk JA; Ogawa K
    Tumori; 2014; 100(3):265-71. PubMed ID: 25076236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
    Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
    Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
    Büntzel J; Glatzel M; Kuttner K; Weinaug R; Fröhlich D
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):4-13. PubMed ID: 11917277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design.
    Samuels MA; Chico IM; Hirsch RL; Fullmer K;
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):94-5. PubMed ID: 14727248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine.
    Chao KS; Ozyigit G; Thorsdad WL
    Semin Oncol; 2003 Dec; 30(6 Suppl 18):101-8. PubMed ID: 14727250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative pelvic hypofractionated accelerated radiotherapy with cytoprotection (HypoARC) for high-risk or recurrent prostate cancer.
    Koukourakis MI; Papadopoulou A; Abatzoglou I; Panteliadou M; Sismanidou K; Touloupidis S
    Anticancer Res; 2012 Oct; 32(10):4561-8. PubMed ID: 23060587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrarectal application of amifostine for the prevention of radiation-induced rectal injury.
    Ben-Josef E; Han S; Tobi M; Vargas BJ; Stamos B; Kelly L; Biggar S; Kaplan I
    Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):81-5. PubMed ID: 11917290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
    Anné PR
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
    Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.